These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ. J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):366-73. PubMed ID: 25055819 [Abstract] [Full Text] [Related]
3. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ. J Neurooncol; 2016 Jan; 126(2):347-54. PubMed ID: 26547911 [Abstract] [Full Text] [Related]
4. Temozolomide in low-grade gliomas: living longer and better. Rees J. J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):359-60. PubMed ID: 25189160 [No Abstract] [Full Text] [Related]
5. Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, Kesari S. Epilepsy Res; 2011 Aug; 95(3):270-2. PubMed ID: 21549564 [Abstract] [Full Text] [Related]
10. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128 [Abstract] [Full Text] [Related]
11. An extent of resection threshold for seizure freedom in patients with low-grade gliomas. Xu DS, Awad AW, Mehalechko C, Wilson JR, Ashby LS, Coons SW, Sanai N. J Neurosurg; 2018 Apr; 128(4):1084-1090. PubMed ID: 28548599 [Abstract] [Full Text] [Related]
12. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, Bertero L, Cassoni P, Soffietti R. J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015 [Abstract] [Full Text] [Related]
13. Delirium likely caused by interaction between phenytoin and temozolomide. Levy M. Psychosomatics; 2007 Oct; 48(4):359-60. PubMed ID: 17600176 [No Abstract] [Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F. Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [Abstract] [Full Text] [Related]
15. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM. Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675 [Abstract] [Full Text] [Related]
17. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. Redjal N, Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J, Nahed BV. J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093 [Abstract] [Full Text] [Related]